DNA Repair Inhibitor & Irradiation on Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Local Metastatic Melanoma
Interventions
DRUG

DT01

"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."

Trial Locations (12)

13385

Hôpital de la Timone, Marseille

33075

Hôpital Saint-André, Bordeaux

44093

Hôpital hôtel-Dieu, Nantes

59020

Centre Oscar Lambret, Lille

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75006

Groupe Hospitalier Cochin - Hôtel Dieu-Broca, Paris

75248

Institut Curie, Paris

75475

Hôpital Saint-Louis, Paris

75877

APHP Hôpital Bichat - Claude Bernard, Paris

76031

Hôpital Charles Nicolle, Rouen

92104

Hôpital Ambroise Paré, Boulogne-Billancourt

06202

CHU de Nice - Archet 2, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DNA Therapeutics

INDUSTRY